bullish
ERIS Lifesciences – FY18 Annual Report Analysis - Strong Rebound in Cash Flow Likely from FY19E
443 Views12 Oct 2018 20:22
We reviewed the FY18 Annual Report of Eris Lifesciences (ERIS IN). Eris reported the negative free cash flow of ~Rs 3,148 mn due to business...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
Trivikram Consultants
Picking Long Term Multi-bagger stocks
Price Chart(Sign Up to Access)
- Eris Lifesciences - 2QFY19 – Acquisitions Drive Top Line Much Higher, Bottom Line to Follow by FY20E17 Nov 2018
- ERIS Lifesciences – FY18 Annual Report Analysis - Strong Rebound in Cash Flow Likely from FY19E12 Oct 2018
- Eris Lifesciences - 1QFY19 – Strides Assimilation on Track21 Aug 2018
- Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track31 May 2018
- ERIS Lifesciences Limited – Acquisition Led Growth Story14 Mar 2018
x